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The	health	of	mammals	is	a	reflection	of	the	diversity	and	composition	of	the	intestinal	
microbiota.	Alterations	in	the	composition	and	functions	of	the	intestinal	microbiota	
have	been	implicated	in	multiple	disease	processes.	The	impact	of	the	microbiota	in	
health	and	disease	is	in	part	a	function	of	the	nutrient	processing	and	release	of	me-
tabolites.	Recent	studies	have	uncovered	a	major	role	for	microbial	metabolites	in	the	
function	of	the	host	immune	system	by	which	they	influence	disease	processes	such	
as	acute	graft	versus	host	disease	(GVHD),	which	is	the	main	complication	of	alloge-
neic	hematopoietic	cell	transplantation	(allo-	HCT).	The	mechanisms	of	acute	GVHD	
regulation	by	the	complex	microbial	community	and	the	metabolites	released	by	them	
are	unclear.	In	this	review	we	summarize	major	findings	of	how	microbial	metabolites	
interact	with	 the	 immune	 system	 and	discuss	 how	 these	 interactions	 could	 impact	
acute	GVHD.
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1  | INTRODUCTION
The	 human	 body	 is	 colonized	 by	 communities	 of	 microorganisms	
termed	the	“microbiota,”	which	include	bacteria,	fungi,	and	viruses	and	
the	gut	is	the	main	site	of	microbial	colonization.1	In	this	review	we	will	
focus	on	 the	 intestinal	microbiota.	The	 intestinal	microbiota	 is	com-
prised	of	 trillions	of	 a	diverse	 community	of	microorganisms	 largely	
consisting	of	nonpathogenic	anaerobic	commensal	bacteria.1 In recent 
years,	high	throughput	sequencing	technologies	have	made	it	possible	
to	analyze	a	large	number	of	microorganisms	in	the	gut.	Bacteroidetes	
and	 Firmicutes	 are	 the	most	 prevalent	 bacterial	 phyla	 in	 the	 intes-
tine	but	Actinobacteria,	Proteobacteria,	and	Verrucomicrobia	are	also	
present.1	The	microbiota	and	the	host	interact	in	delicate	harmony	to	
create	a	healthy	balanced	 state	and	disturbances	of	 this	mutualistic	
symbiotic	balance	have	been	 linked	to	a	range	of	diseases	 including	
obesity,	inflammatory	bowel	disease,	colorectal	cancer,	and	diabetes.1
Allogeneic	hematopoietic	cell	 transplantation	 (Allo-	HCT)	 is	a	po-
tentially	 curative	 treatment	 modality	 for	 patients	 with	 a	 variety	 of	
malignant	and	benign	hematological	diseases.	However,	the	effective-
ness	of	allo-	HCT	is	limited	by	acute	graft	versus	host	disease	(GVHD)	
which	 is	 the	principal	 cause	of	 non-	relapse	mortality.2	Conditioning	
regimens	 used	 in	 allo-	HCT	 cause	 host	 tissue	 injuries	which	 release	
“danger	 signals”	 that	activate	host	or	donor	antigen	presenting	cells	
(APCs)	 which	 in	 turn	 present	 allo-	antigens	 via	 major	 histocompati-
bility	complex	(MHC)	class	 I	or	class	 II	to	donor	T	cells.3	 In	addition,	
activated	 APCs	 produce	 T-	cell	 stimulating	 cytokines	 which	 further	
escalate	the	inflammatory	response.	Stimulated	donor	T	cells	expand	
and	differentiate	into	effector	T	cells	which	migrate	into	and	damage	
acute	GVHD	target	organs	such	as	the	gastrointestinal	(GI)	tract.	The	
activation	of	APCs	is	amplified	by	microbial	stimulation	via	pathogen-	
associated	molecular	patters	(PAMPs)	and	damage-	associated	molec-
ular	patters	(DAMPs).
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The	 relationship	 between	 the	 intestinal	 microbiota	 and	 acute	
GVHD	has	been	a	topic	of	interest	since	the	1970s	following	seminal	
observations	by	van	Bekkum	et	al	in	experimental	models.4	However,	
scrupulous	examination	of	this	relationship	has	become	possible	only	
recently	with	advances	 in	high	throughput	sequencing	technologies.	
Emerging	data	suggest	that	alterations	in	the	intestinal	microbiota	and	
microbial	metabolites	may	play	important	roles	in	modulating	the	se-
verity	of	acute	GVHD.	 In	 this	 review,	we	summarize	these	data	and	
recent	 efforts	 that	 investigated	 the	 roles	 of	 the	 intestinal	microbial	
metabolites	in	shaping	the	host	immune	system	as	well	as	discuss	po-
tential	new	avenues	for	exploring	these	roles	in	intestinal	acute	GVHD.
2  | INTESTINAL MICROBIOTA
Herein,	we	briefly	discuss	intestinal	microbiota	and	its	role	in	interact-
ing	with	the	 immune	system	and	modulating	 intestinal	homeostasis.	
We	would	refer	readers	to	recent	reviews	that	have	covered	this	topic	
in	depth.1,5	Microbiota-	host	 immune	system	 interactions	are	 impor-
tant	mediators	of	both	tolerance	and	protection.	Maintaining	this	equi-
librium	between	the	host	and	the	microbiome	involves	the	innate	and	
adaptive	immune	systems	as	well	as	other	non-	immunologic	defensive	
tactics	such	as	the	release	of	antimicrobial	peptides	(AMPs)	and	the	
generation	of	the	mucus	barrier.5	Many	immune	cells	are	involved	in	
this	mutualistic	 interactions,	 include	 immune	cells	 isolated	 lymphoid	
follicles	(ILFs),	peyer’s	patches	(PPs),	mesenteric	lymph	nodes	(MLNs),	
and	lamina	propria	immune	cells	such	as	macrophages,	dendritic	cells	
(DCs),	T	cells,	B	cells,	and	innate	lymphoid	cells	(ILCs).	Lamina	propria	
macrophages	phagocytose	and	eliminate	bacteria	that	penetrate	the	
intestinal	epithelial	cell	(IEC)	barrier.	Lamina	propria	DCs	engulf	pen-
etrant	bacteria,	traffic	to	secondary	lymphoid	tissues	such	as	PPs	and	
MLNs,	and	induce	T	and	B	cell	responses.	In	response	to	commensal	
bacteria,	IECs	produce	cytokines	which	promote	the	development	of	
macrophages	and	DCs	with	tolerogenic	properties.	ILCs	are	also	im-
portant	 for	 intestinal	 immune	homeostasis	 and	 are	 classified	 into	3	
groups.1,5	Retinoic	acid	receptor-	related	orphan	receptor-	γt	(RORγt)+ 
group	3	innate	lymphoid	cells	(ILC3s)	regulate	commensal	bacteria	by	
limiting	 local	and	systemic	 inflammation.	RORγt+	 ILC3s	produce	the	
epithelial	cell	regenerative	factor	IL-	22	in	response	to	IL-	23	produced	
by	myeloid	cells.	Disturbances	of	immune	structures	can	result	in	dys-
biosis	of	the	 intestinal	microbiota.	For	example,	the	absence	of	ILFs	
altered	the	composition	of	the	 intestinal	microbiota	 in	mice	by	over	
representation	of	gram	negative	bacteria.6	The	 intestinal	microbiota	
in	turn	shapes	the	innate	and	adaptive	host	immune	responses.	Germ	
free	 mice	 colonized	 with	 conventional	 intestinal	 microbiota	 devel-
oped	innate	immune	responses	and	structural	changes	with	increase	
in	 the	 depth	 of	 the	 intestinal	 epithelial	 crypts	 as	well	 as	 expansion	
in	 the	 lamina	propria	with	an	 increase	 in	 the	 immune	cells	within	4	
days	after	exposure	to	intestinal	bacteria.7	The	intestinal	microbiota	
was	also	linked	to	the	regulation	of	adaptive	immune	cells	as	intesti-
nal	commensal	microbes	were	shown	to	induce	forkhead	box	protein	
(Foxp3)-	 expressing	 regulatory	 T	 cells	 (Tregs)	which	 produce	 IL-	10,	
an	 anti-	inflammatory	 cytokine.8	 In	 contrast,	 stimuli	 associated	with	
pathogenic	bacteria	cause	 inflammatory	responses	via	 IL-	1	and	 IL-	6	
induction	which	result	in	Th1	and	Th17	activation.1,5
Non-	immune	 intestinal	 cells	 such	 as	 intestinal	 epithelial	 cells	
(IECs),	Goblet	cells,	Paneth	cells	and	 intestinal	 stem	cells	 (ISCs)	play	
important	roles	in	regulating	the	barrier	function	of	the	GI	tract	and	
the	 intestinal	microbiota	has	been	 shown	 to	promote	 the	 functions	
of	 these	 cells.	 IECs	 form	 a	 continuous	 physical	 barrier	 to	 separate	
luminal	organisms	from	intestinal	tissues	and	ISCs	play	an	important	
role	in	maintaining	the	turnover	of	IECs.1	Germ-	free	mice	show	slower	
turnover	of	 IECs	compared	with	conventionally	raised	mice.7	Goblet	
cells	protect	the	epithelium	from	luminal	bacteria	by	mucin	secretion.1 
Commensal	microbes	enhance	mucin	production	by	goblet	cells	while	
germ-	free	mice	show	markedly	reduced	levels	of	mucin.	Paneth	cells	
secrete	AMPs	such	as	α-	defensins	and	RegIIIα	in	response	to	bacteria	
and	their	antigens	and	play	a	role	in	shaping	the	intestinal	microbiota.
3  | MICROBIAL METABOLITES
The	intestinal	metabolome	consists	of	products	from	host	metabolism,	
microbial	 metabolism,	 and	 mammalian–microbial	 co-	metabolism.9 
Microbial	metabolites	have	varying	functions	in	the	gut	and	they	in-
clude	a	diverse	repertoire	of	intermediate	and	end	products	of	both	
diet-	dependent	as	well	as	diet-	independent	intestinal	microbiota	me-
tabolism.	The	non-	dietary	products	are	generated	by	metabolism	of	
endogenous	compounds	produced	by	microorganisms	and	the	host.	
Herein	we	will	 focus	 on	 the	 diet	 dependent	metabolites	which	 are	
generated	by	 the	breakdown	of	 the	host	nutrients	by	 the	 intestinal	
microbes.
3.1 | Short chain fatty acids
Anaerobic	 commensal	 bacteria	 such	 as	 Clostridia	 species	 produce	
short	chain	fatty	acids	 (SCFAs)	 from	fermentation	of	non-	digestible	
carbohydrates.10	SCFAs	are	 the	most	 studied	microbial	metabolites	
and	 include	 butyrate,	 acetate,	 and	 proprionate.	 They	 serve	 as	 an	
energy	 source	 for	 the	 intestinal	microbiota	as	well	 as	 the	 IECs	and	
are	recognized	by	the	host	through	the	G	protein-	coupled	receptors	
GPR41,	GPR43,	and	GPR109a.	Butyrate	is	an	energy	source	for	IECs	
as	colonocytes	from	germ-	free	mice	were	shown	to	be	in	an	energy-	
deprived	state	which	 led	 to	autophagy	whereby	 the	cells	degraded	
their	own	components	in	order	to	maintain	energy	homeostasis	and	
this	 was	 reversed	 by	 butyrate	 supplementation.11	 Besides	 provid-
ing	IECs	with	an	energy	source,	SCFAs	are	essential	for	maintaining	
the	 integrity	of	 the	 intestinal	mucosal	barrier	 through	 regulation	of	
functions	of	goblet	cells.12	The	barrier	 integrity	of	 IECs	was	further	
shown	 to	 be	maintained	 by	 the	 SCFA	 acetate	 as	 colonization	with	
Bifidobacterium longum	protected	mice	against	death	induced	by	a	le-
thal	infection	by	increasing	production	of	acetate	and	inhibiting	trans-
location	of	the	E.	coli	O157:H7	Shiga	toxin	from	the	gut	lumen	into	
the	blood.13	In	addition	to	their	functions	in	maintaining	the	health	of	
the	barrier	surface	of	the	GI	tract,	microbial	metabolites	play	various	
roles	in	modulating	the	innate	and	adaptive	host	immune	responses	
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(Figure	1).	 SCFAs	 such	 as	 butyrate	 play	 an	 integral	 part	 in	 innate	
immunity	 as	 they	 are	 histone	 deacetylase	 (HDAC)	 inhibitors	 that	
promote	 an	 anti-	inflammatory	 cell	 phenotype.	 GPCR43	 expression	
was	shown	to	be	necessary	 for	 the	effects	of	SCFAs	on	neutrophil	
chemotaxis.14	Other	studies	showed	that	SCFAs	inhibit	HDACs	and	
have	 anti-	inflammatory	 effects	 in	 macrophages	 and	 dendritic	 cells	
(DCs).15,16	In	the	study	by	Macia	et	al,	a	high	fiber	diet	or	treatment	
with	the	SCFA	acetate	in	mice	increased	inflammasome	activation	and	
increased	levels	of	IEC	protective	IL-	18	in	a	GPR43-	and	GPR109a-	
dependent	manner	which	 promoted	 epithelial	 repair	 and	mitigated	
the	 severity	 of	 inflammatory	 colitis.17	 Besides	 their	 involvement	 in	
innate	immune	responses,	SCFAs	were	shown	to	modulate	the	adap-
tive	 arm	of	 intestinal	 immunity.	 Specifically,	 SCFAs	were	 shown	 to	
promote	Treg	differentiation,	promote	anti-	inflammatory	 responses	
and	suppress	T	cell	dependent	experimental	colitis.8	Administration	
of	butyrate,	acetate,	and	proprionate	to	germ-	free	mice	increased	the	
expression	 of	 anti-	inflammatory	 IL-	10	 producing	 Foxp3-	expressing	
Tregs	 through	 HDAC	 inhibition	 in	 a	 GPR43	 dependent	 manner.5 
Additionally,	butyrate	enhanced	the	expression	of	IL-	18	on	IECs	and	
increased	IL-	10	expression	that	was	critical	for	protection	from	colitis	
in	a	GPR109a-	dependent	manner.18
3.2 | Bile acids
Another	 group	 of	 microbial	 metabolites	 that	 regulate	 immunity	 in-
clude	bile	 acids.	 They	 are	 synthesized	 from	 cholesterol	 in	 the	 liver,	
conjugated	to	glycine	in	humans	or	taurine	in	mice,	and	further	metab-
olized	by	the	intestinal	microbiota	into	secondary	bile	acids.19	Bile	acid	
F IGURE  1 Microbial	metabolites	maintain	the	health	of	the	intestinal	barrier	surface	and	modulate	immune	responses.	Short	chain	fatty	
acids	(SCFAs)	enhance	epithelial	barrier	function	and	immune	tolerance	by:	serving	as	an	energy	source	for	intestinal	epithelial	cells	(IECs);	
modulating	autophagy;	enhancing	production	of	mucus	by	intestinal	Goblet	cells;	increasing	inflammasome	activation	and	subsequent	
production	of	IL-	18;	inhibiting	histone	deacetylase	(HDAC);	inhibiting	nuclear	factor-	κB	(NF-	κB);	increasing	anti-	inflammatory	effects	in	
macrophages	and	dendritic	cells	(DCs);	increasing	differentiation	of	regulatory	T	cells	(Tregs)	and	their	production	of	IL-	10.	Bile	acids	enhance	
epithelial	barrier	function	and	inhibit	pro-	inflammatory	cytokines	via	NF-	κB	inhibition.	Polyamines	augment	the	barrier	integrity	of	IECs,	inhibit	
pro-	inflammatory	cytokines	and	modulate	the	adaptive	immune	system	by	accelerating	the	maturation	of	T	cell	subsets	in	newborn	rats.	Aryl	
hydrocarbon	receptor	(AhR)	ligands	enhance	the	turnover	of	IECs	and	expand	innate	lymphoid	cells	(ILCs)	and	their	production	of	the	epithelial	
cell	regenerative	factor	IL-	22.
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signaling	is	controlled	by	the	intestinal	microbiota	through	two	main	
receptors:	the	nuclear	farnesoid	X	receptor	(FXR)	and	the	G	protein-	
coupled	 bile	 acid	 receptor	 1	 (GPBAR1)	 also	 known	 as	 TGR5.	Mice	
lacking	 FXR	 show	 compromised	 epithelial	 barrier	 function	 and	 en-
hanced	bacterial	translocation	from	the	intestine.20	Bile	acids	activate	
TGR5	 on	 macrophages	 and	 inhibit	 production	 of	 pro-	inflammatory	
cytokines	such	as	TNFα	and	Il-	1β	via	nuclear	factor	κB	(NF-	κB)	inhibi-
tion.21	Furthermore,	administration	of	saturated	fatty	acids	to	 IL-	10	
deficient	mice	altered	the	composition	of	the	intestinal	microbiota	and	
enhanced	pro-	inflammatory	TH1	response	and	the	severity	of	colitis.
22
3.3 | Polyamines
Polyamines	are	polycationic	molecules	that	are	found	in	high	concen-
trations	in	the	GI	tract	and	are	derived	from	both	host	and	intestinal	
microbiota	metabolism.	They	have	been	implicated	in	a	wide	range	of	
biological	 functions.23	 Importantly,	 polyamines	were	 shown	 to	 aug-
ment	the	barrier	integrity	of	IECs.24	They	also	play	a	role	in	innate	im-
munity.	The	polyamine	spermine	was	shown	to	inhibit	the	activation	
of	the	pro-	inflammatory	phenotype	of	macrophages	and	suppress	the	
synthesis	of	pro-	inflammatory	cytokines	without	altering	the	synthe-
sis	 of	 anti-	inflammatory	 cytokines	 transforming	 growth	 factor-	beta	
(TGF-	β)	 and	 IL-	10.25	Moreover,	 oral	 administration	 of	 the	 probiotic	
bifidobacteria	 LKM512	 in	 combination	 with	 the	 amino	 acid	 argi-
nine,	which	 is	metabolized	 to	 produce	 polymaines,	 increased	 levels	
of	polyamines,	 improved	longevity,	and	protected	from	age-	induced	
memory	 impairment	 in	mice	which	correlated	with	decreased	 levels	
of	pro-	inflammatory	cytokines.26	Polyamines	also	modulate	adaptive	
immunity	as	the	oral	supplementation	of	the	polyamines	spermine	or	
spermidine	to	newborn	rats	accelerated	the	maturation	of	intraepithe-
lial	CD8+	T	cells,	increased	the	percentage	of	lamina	propria	CD4+	T	
cells,	and	enhanced	B	cells	in	the	spleen.27
3.4 | Aryl hydrocarbon receptor ligands
Aryl	hydrocarbon	receptor	(AhR)	is	a	ligand-	activated	transcription	
factor	and	a	modulator	of	mucosal	immune	responses.	AhR	ligands	
are	derived	from	intestinal	microbiota	metabolism.	The	commensal	
Lactobacilli	utilizes	amino	acid	 tryptophan	 to	produce	AhR	 ligands	
such	as	 indole-	3-	aldehyde.28	AhR	 ligands	are	critical	 for	 the	main-
tenance	of	the	intestinal	epithelial	barrier.	Their	deficiency	in	mice	
results	 in	alterations	of	 the	 intestinal	microbiota	composition	with	
bacterial	 overgrowth,	 decrease	 in	 AMPs	 and	 intestinal	 epithelial	
lymphocytes	 (IELs),	 and	 reduced	 turnover	 of	 IECs.29	 AhR	 directly	
regulates	 innate	 immunity.	 It	 is	 necessary	 for	 expansion	 of	 IL-	22	
producing	 RORγt+	 ILC3s	 and	 the	 formation	 of	 ILFs,	 which	 were	
needed	for	the	clearance	of	Citrobacter rodentium	 infection.30	AhR	
effect	on	RORγt+	 ILC3s	can	be	 induced	by	dietary	 ligands	such	as	
those	 contained	 in	 vegetables	 of	 the	 family	 Brassicaceae.30	 They	
were	also	shown	to	be	important	in	adaptive	immunity.	A	reduction	
in	AhR	 ligands	 in	 response	 to	Cyp1a1	enzyme	activity	 in	 the	 IECs	
decreased	Th17	cells	and	impaired	Il-	22	production	in	response	to	
enteric	infections.31
4  | INTESTINAL MICROBIOTA AND ACUTE  
GVHD
A	healthy	intestinal	microbiota	is	diverse	and	dominated	by	obligate	
anaerobic	 bacteria.1	 During	 the	 process	 of	 allo-	HCT	 patients	 lose	
this	 diversity	 and	 experience	 alterations	 in	 community	 composition	
which	are	influenced	by	antibiotic	treatment	and	the	development	of	
acute	GVHD.32-34	Holler	et	al	showed	a	shift	towards	Enterococci	after	
allo-	HCT	with	a	decrease	in	the	obligate	anaerobic	bacteria	from	the	
phylum	Frimicutes	 that	was	pronounced	 in	 those	 that	were	 treated	
with	antibiotics.32	Thus	the	process	of	allo-	HCT	has	been	shown	to	
alter	 the	 intestinal	microbiota	 composition	 and	 affect	 the	 intestinal	
homeostasis.
Reciprocally,	 the	 intestinal	microbiota	 has	 been	 shown	 to	mod-
ulate	 post	 allo-	HCT	 outcomes	 including	 acute	 GVHD.35-38	 Studies	
from	 the	1970s	 investigated	 the	 role	of	 the	 intestinal	mcirobiota	 in	
allo-	HCT	and	found	 less	acute	GVHD	in	mice	transplanted	 in	germ-	
free	 conditions	 or	 receiving	 gut	 decontamination	 antibiotics.4	 Some	
follow-	up	clinical	studies	showed	similar	beneficial	effects	of	bacterial	
decontamination	 in	allo-	HCT	patients	while	a	 few	others	did	not.39-
42	The	 reasons	 for	 these	disparate	 results	 remain	 unclear	 but	 could	
be	due	to	variation	in	success	of	decontamination	techniques	or	the	
specifics	of	the	alteration	 in	the	microbiota	composition	rather	than	
just	 a	 global	 loss	 of	 diversity.	 Recent	 studies	 show	 that	 changes	 in	
microbial	composition	post	allo-	HCT	were	more	pronounced	in	those	
that	 developed	 acute	 GVHD	 including	 greater	 loss	 of	 diversity,	 ex-
pansion	 of	 Enterobacteriales,	 Lactobacillales,	 Proteobacteria,	 and	
Akkermansia.43,44	 This	was	 accompanied	 by	 the	 loss	 of	 obligate	 an-
aerobic	bacteria	from	the	phylum	Firmicutes	(including	Clostridia	and	
Blautia).	 High	 intestinal	 abundance	 of	Blautia	 correlated	with	 lower	
rates	of	acute	GVHD	and	improved	survival.36	It	was	recently	shown	
that	administration	of	a	cocktail	of	17	species	of	Clostridia	 reduced	
experimental	acute	GVHD	and	 improved	survival.45	These	data	sug-
gest	that	changing	the	microbial	architecture	in	the	right	manner	may	
be	a	potentially	novel	approach	for	ameliorating	acute	GVHD.	In	line	
with	this	notion,	treating	acute	GVHD	in	allo-	HCT	patients	with	fecal	
microbiota	transplant	(FMT)	is	currently	being	investigated	in	clinical	
trials	 (www.clinicaltrials.gov:	NCT02269150,	NCT02733744).	Of	 in-
terest,	recent	very	small	studies	suggested	that	FMT	after	allo-	HCT	is	
safe	and	may	have	clinical	impact	in	patients	with	advanced	acute	GI	
GVHD.46-48
Most	of	the	aforementioned	studies	of	the	effect	of	the	microbi-
ota	on	acute	GVHD	are	based	on	associations	but	the	causations	and	
potential	mechanisms	of	how	the	microbiota	modulates	acute	GVHD	
severity	remain	unknown.	Host	microbial	sensing	by	pathogen	recog-
nition	 receptors	 (PRRs)	 has	been	 suggested	 to	play	 a	 role	 in	modu-
lating	experimental	acute	GVHD.3	For	example	donor	cell	responses	
to	PAMPs,	such	as	 lipopolysaccharides	 (LPS),	amplifies	experimental	
acute	GVHD.3	In	humans,	TLR4	polymorphisms	were	associated	with	
lower	risk	of	acute	GVHD.43	TLR9	was	shown	to	play	a	role	in	an	ex-
perimental	model	of	acute	GVHD.	Similarly,	NOD2	was	reported	to	be	
associated	with	acute	experimental	and	clinical	acute	GVHD.3	The	role	
of	PRRs	 in	acute	GVHD	has	been	covered	 in	other	 recent	 reviews.3 
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Nonetheless	the	PRRs	do	not	completely	allow	for	understanding	the	
changes	in	microbial	communities	and	their	causal	role,	if	any,	in	acute	
GVHD	severity.
5  | MICROBIAL METABOLITES AND 
ACUTE GVHD
The	 changes	 in	microbiome	 structure	 cause	 a	 change	 in	 intestinal	
metabolites.	A	recent	study	explored	the	role	of	microbial	metabo-
lites	 in	 acute	GVHD	 severity.45	 The	 study	 reported	data	 primarily	
on	 SCFAs	 and	 long	 chain	 fatty	 acids	 (LCFAs)	 from	 skin,	 intestine	
and	liver	post	experimental	allo-	HCT.	The	study	demonstrated	that	
amongst	 all	 the	 SCFAs	 and	 LCFAs	 from	various	 tissues	 and	 stool,	
only	the	SCFA	butyrate	was	significantly	decreased	only	in	the	IECs.	
The	impact	on	non	fatty	acid	metabolites	was	not	reported.	The	re-
duction	 in	 the	 IEC	 butyrate	was	 associated	with	 reduction	 in	 the	
microbial	diversity	and	 in	the	family	of	bacteria	that	are	known	to	
produce	butyrate	from	resistant	starch.	An	interesting	aspect	of	the	
study	was	 that	 the	diet	was	kept	 constant.	 It	 remains	unknown	 if	
changing	the	diet	to	resistant	starch,	the	fodder	for	bacterial	species	
that	break	it	down	to	butyrate,	might	alter	the	butyrate.	However,	
the	 study	 reported	 that	 supplementing	 the	 microbiome	 with	 17	
strains	of	clostridial	species	that	are	known	to	be	butyrate	produc-
ers	restored	butyrate	levels	in	both	antibiotic	treated	or	untreated	
recipients.	 Furthermore,	 the	 restoration	 of	 butyrate	 levels	 with	
exogenous	administration	of	butyrate	without	changing	the	micro-
biome	promoted	histone	acetylation	 in	 IECs	and	caused	enhanced	
expression	 of	 anti-	apoptotic	 proteins	 involved	 in	 barrier	 integrity	
such	as	JAM	and	occludin.	Importantly,	butyrate	administration	in-
creased	 the	 expression	 of	 its	 surface	 receptor,	 GPR43	 and	 trans-
porter	protein,	SLC5A8.	Most	relevantly,	 restoring	butyrate	 levels,	
either	by	direct	administration	of	butyrate	or	by	changing	 the	mi-
crobiome	with	increasing	butyrogenic	bacteria	such	as	with	the	17	
strains	 of	 Clostridia,	 mitigated	 intestinal	 barrier	 damage,	 reduced	
acute	GVHD	specific	damage,	and	improved	survival	after	allo-	HCT.	
Mechanistically,	 butyrate	 increased	 histone	 acetylation	 and	 was	
also	rapidly	metabolized	by	the	IECs	after	allo-	HCT.	Ex	vivo	studies	
showed	that	the	IECs,	upon	treatment	with	SCFA	butyrate,	showed	
a	reduction	with	apoptosis	when	cultured	with	alloreactive	T	cells.	
Intriguingly,	the	reduction	in	acute	GVHD	was	observed	even	when	
the	donor	Tregs	were	depleted	 from	 the	donor	 cells.	While	 these	
data	 suggest	protective	effects	on	acute	GVHD	could	occur	 inde-
pendent	 of	 donor	 Tregs,	 the	 study	 did	 not	 explore	 whether	 host	
Tregs	 played	 a	 role	 in	 acute	 GVHD	 protection.	 However,	 the	 re-
port	 suggests	 that	 direct	 effect	 of	 butyrate	 on	 IECs	might	 play	 a	
role	 in	 reducing	 acute	GVHD	 severity.	 This	 concept	 is	 now	being	
studied	in	two	clinical	trials	(www.clinicaltrials.gov:	NCT02763033,	
NCT02805075).	Of	 interest,	 one	 small	 study	 in	 20	 healthy	 young	
adults	showed	that	potato-	based	starches	induce	production	of	bu-
tyrate	from	the	microbiota.49	A	clinical	trial	of	this	prebiotic	aimed	at	
increasing	butyrate	levels	and	prevention	of	acute	GVHD	is	under-
way	(www.clinicaltrials.gov:	NCT02763033).
Currently	 there	 is	 paucity	 of	 data	 on	 other	 intestinal	 microbial	
metabolites	and	their	impact	in	acute	GVHD	(Table	1).	However,	one	
clinical	study	 in	allo-	HCT	patients	showed	that	 lower	 levels	of	urine	
3-	indoxyl	sulfate,	a	metabolite	derived	from	indole	produced	by	com-
mensal	bacteria	and	an	AhR	ligand,	correlated	with	higher	treatment	
related	mortality	and	lower	overall	survival.50
6  | FUTURE PERSPECTIVES
The	aforementioned	recent	study	which	explored	the	role	of	microbial	
metabolites	in	acute	GVHD	severity45	raises	several	interesting	ques-
tions	 including,	but	not	 limited	 to,	whether	 it	 is	possible	 to	mitigate	
GI	damage	by	directly	affecting	target	cells	without	substantially	af-
fecting	the	immune	system.51	Do	other	SCFAs	a	role	or	is	this	unique	
to	butyrate?	 If	 so,	 then	 is	butyrate	protective	primarily	by	 inhibiting	
HDACs	and/or	by	providing	energy	to	the	IECs	under	duress	from	in-
flammation?	This	study	demonstrated	that	microbial	metabolites	are	
critical	and	suggest	these	are	relevant	causal	mediators	of	the	micro-
bial	changes	associated	with	acute	GVHD	severity.45	It	opens	up	ques-
tions	for	the	putative	roles	of	other	metabolites,	their	correlation	and	
relationship	to	the	dynamics	of	microbiome	alterations,	the	role	of	sen-
sors	of	these	metabolites,	the	impact	of	these	on	immune	system,	on	
IECs,	ISCs,	Paneth	cells,	and	other	tissues	in	acute	GVHD.	Of	particular	
interest,	AhR	was	necessary	for	expansion	of	IL-	22	producing	ILCs.30 
IL-	22	is	an	epithelial	cell	regenerative	factor	and	IL-	22	producing	ILCs	
were	found	to	be	depleted	in	the	intestines	of	mice	with	acute	GVHD	
and	 treatment	with	 IL-	22	enhanced	 the	 recovery	of	 ISCs,	 increased	
epithelial	regeneration,	and	reduced	acute	GVHD.52	Administration	of	
IL-	22	along	with	systemic	corticosteroids	is	now	being	investigated	in	
a	clinical	trial	for	initial	treatment	of	grade	II-	IV	lower	GI	acute	GVHD	
(www.clinicaltrials.gov:	NCT02406651),	but	the	role	that	AhR	plays	in	
modulating	IL-	22	producing	ILCs	in	acute	GVHD	and	whether	dietary	
ligands	can	modulate	that	role	are	yet	to	be	investigated.	Additionally,	
several	microbial	metabolites	can	impact	adaptive	immune	responses	
and	promote	Treg	differentiation5,8,18,	which	 is	of	particular	 interest	
given	that	Tregs	suppress	acute	GVHD2	and	warrants	further	 inves-
tigation.	In	summary,	more	investigations	of	the	role	of	microbial	me-
tabolites	in	GVHD	are	needed.
TABLE  1 Microbial	metabolites	involved	in	maintaining	the	health	
of	the	intestinal	barrier	surface	and	modulating	immune	responses	
and	their	known	roles	in	acute	graft	versus	host	disease	(GVHD)
Microbial metabolites Roles explored in acute GVHD
Short	chain	fatty	acids	(SCFA) Direct	effect	of	the	SCFA	butyrate	
on	intestinal	epithelial	cells	(IECs):	
reduced	severity	of	experimental	
intestinal	acute	GVHD
Bile	acids To	be	determined
Polyamines To	be	determined
Aryl	hydrocarbon	receptor	
(AhR)	ligands
Low	levels	of	urine	3-	indoxyl	
sulfate	correlated	with	increased	
clinical	intestinal	acute	GVHD
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